IP Library Granted Patent US 12,083,339
Granted Patent B2
US 12,083,339 · App. 16/340,106 · Granted Sep 10, 2024

Induced cell morphology electroporation

Inventors: Jill W. Ivey (Blacksburg, VA); Eduardo L. Latouche (Blacksburg, VA); Scott S. Verbridge (Blacksburg, VA); Rafael V. Davalos (Blacksburg, VA); Glenn J. Lesser (Winston-Salem, NC); Waldemar Debinski (Blacksburg, VA)
Assignees: Virginia Tech Intellectual Properties, Inc.; Wake Forest University Health Sciences
A61N1/327A61B18/12A61B18/1233A61K38/19A61N1/05A61N1/06A61B2017/00172A61B2018/00613A61B2018/00732A61B2018/00767A61B2018/126A61B2018/128A61K38/1793
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,083,339
App. No.
16/340,106
Granted
Sep 10, 2024
Kind
B2
Abstract

Described herein are methods of electroporation that can include the steps of contacting a cell that is responsive to an EphA2 receptor ligand with an amount of an EphA2 receptor ligand and applying high-frequency irreversible electroporation to the cell. Also described herein are methods of treating cancer in a subject in need thereof, wherein the methods can include the steps of administering an amount of an EphA2 receptor ligand and applying high-frequency irreversible electroporation to a location on or within the subject.

Claims (27)

1. A method of enhancing electroporation comprising:

inducing a targeted morphology change in one or more target cells expressing an EphA2 receptor by contacting the one or more target cells with an amount of an EphA2 receptor ligand, wherein the targeted morphology change is a reduction in cytoplasmic size thereby generating an increase in the ratio of nucleus to cytoplasmic size (NCR), and wherein the EphA2 receptor ligand is effective to induce the targeted morphology change; and

applying, to cells in the plurality of cells expressing the EphA2 receptor ligand and having an increased NCR after contacting the cell, a high-frequency irreversible electroporation (H-FIRE) pulse train.

2. The method of claim 1 , wherein the H-FIRE pulse train comprises:

one or more bursts of bipolar electric pulses, wherein each burst comprises

two or more electric waveform pulses that alternate polarity with each successive electrical waveform pulse,

wherein each electric waveform pulse is separated by a delay between each successive electric waveform pulse, and

wherein each electric waveform pulse comprises a carrier frequency in the range of about 1 kHz to about 1 MHz.

3. The method of claim 2 , wherein 1 or 2 bursts are delivered every second.

4. The method of claim 2 , wherein each electric waveform pulse is a square wave.

5. The method of claim 2 , wherein the delay between each successive electric waveform pulse ranges from about 0.5 μs to about 10 μs.

6. The method of claim 2 , wherein the delay between each successive electric waveform pulse is about 5 μs.

7. The method of claim 2 , wherein each electric waveform pulse is applied for about 250 ns to about 2 μs.

8. The method of claim 2 , wherein each electric waveform pulse is applied for about 1 μs.

9. The method of claim 2 , wherein in the carrier frequency is about 200 kHz.

10. The method of claim 2 , wherein an output voltage of the H-FIRE pulse train ranges from about 500 V to about 5000 V.

11. The method of claim 2 , wherein an output voltage of the H-FIRE pulse train results in a voltage-to-distance ratio of about 2000 V/cm.

12. The method of claim 1 , wherein the one or more target cells over express a EphA2 receptor as compared to a normal cell.

13. The method of claim 1 , wherein the one or more target cells are one or more cancer cells.

14. The method of claim 1 , wherein the one or more target cells are one or more malignant cancer cells.

15. The method of claim 1 , wherein the one or more target cells are one or more breast cancer cells, one or more melanoma cells, one or more ovarian cancer cells, one or more lung cancer cells, one or more glioma cells, one or more bladder cancer cells, one or more prostate cancer cells, one or more esophageal cancer cells, one or more renal cancer cells, one or more colon cancer cells, one or more pancreatic cancer cells, or one or more vulvar cancer cells.

16. The method of claim 1 , wherein the EphA2 receptor ligand is an ephrin.

17. The method of claim 1 , wherein the EphA2 receptor ligand is ephrin A1.

18. The method of claim 1 , wherein the one or more target cells are in a subject.

19. A method of selectively ablating one or more target cells responsive to an EphA2 receptor ligand in a subject in need thereof, the method comprising:

administering to the subject an amount of an EphA2 receptor ligand thereby inducing a targeted morphology change in one or more target cells expressing an EphA2 receptor, wherein the targeted morphology change is a reduction in cytoplasmic size thereby generating an increase in the ratio of nucleus to cytoplasmic size (NCR), and wherein the EphA2 receptor ligand is effective to induce the targeted morphology change; and

applying a high-frequency irreversible electroporation (H-FIRE) pulse train to a location on or within the subject after administering the amount of the EphA1 receptor ligand.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 30, 2024
From: VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY
To: VIRGINIA TECH INTELLECTUAL PROPERTIES, INC.
Reel/Frame 067268/0990 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2022
From: DAVALOS, RAFAEL V.
To: VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY
Reel/Frame 061800/0535 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2022
From: LATOUCHE, EDUARDO L.
To: VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY
Reel/Frame 061800/0754 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2022
From: VERBRIDGE, SCOTT S.
To: VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY
Reel/Frame 061800/0790 →
Continuity (2)
Provisional Application 62405089 · Oct 6, 2016
Related Publication 20200046967A1 · Feb 13, 2020